Research Conducted at Second Affiliated Hospital Has Provided New Information about Gastric Cancer (Inetetamab Combined With S-1 and Oxaliplatin As First-line Treatment for Human Epidermal Growth Factor Receptor 2-positive Gastric Cancer).

Researchers at the Second Affiliated Hospital in Shandong, China, conducted a study on the efficacy and safety of Inetetamab combined with S-1 and oxaliplatin as a first-line treatment for HER2-positive advanced gastric cancer. The study involved 38 patients who were randomly divided into two groups, one receiving Inetetamab and the other receiving trastuzumab. Results showed that Inetetamab demonstrated superior progression-free survival compared to trastuzumab, with comparable overall survival rates and adverse event profiles. This research has been peer-reviewed and provides valuable insights into potential treatment options for HER2-positive gastric cancer patients. [Extracted from the article]